Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model

Brain Research

Volumn 886, Issue 1-2, 2000, Pages 82-98

  Bjorklund A ^a   Kirik, D ^a   Rosenblad, C ^b   Georgievska, B ^a   Lundberg, C ^a   Mandel, R J ^c  

^a LUND UNIVERSITY   (Sweden)

^b NsGene AS   (Denmark)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Gene transfer; Glial cell line derived neurotrophic factor; Lentivirus; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DEXAMPHETAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANIMAL MODEL; CELL REGENERATION; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GLIA CELL; HUMAN; LENTIVIRINAE; MONKEY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PERIKARYON; PRIORITY JOURNAL; RAT; REVIEW; SUBSTANTIA NIGRA; VIRUS RECOMBINANT;

EID: 0034672304     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(00)02915-2     Document Type: Article

References (71)

1. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF
2. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
3. Selective and rapid uptake of adeno-associated virus type 2 in brain
4. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF
5. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
6. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease
7. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
8. Adenovirus-mediated transgene expression in nonhuman primate brain
9. Quantitation of glial cell line-derived neurotrophic factor (GDNF) expression in the monkey CNS after injection of an Adenoviral vector (AdGDNF)
10. The early diagnosis of Parkinson's disease
11. Development of lentiviral vectors for gene therapy for human diseases
12. Dopaminergic neurons protected from degeneration by GDNF gene therapy
13. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor
14. Efficient gene transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced with lentiviral vectors
15. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat
16. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors
17. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors
18. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice
19. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
20. A third-generation lentivirus vector with a conditional packaging system
21. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
22. PET studies of functional compensation in a primate model of Parkinson's disease
23. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys
24. Ageing and Parkinson's disease: substantia nigra regional selectivity
25. Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates
26. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
27. Construction of adenovirus vectors through Cre-lox recombination
28. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors
29. Lentiviral vectors: regulated gene expression
30. Immune responses to adenoviral vectors during gene transfer in the brain
31. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
32. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
33. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system
34. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors
35. Lentiviral gene transfer to the nonhuman primate brain
36. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease
37. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats
38. Inflammatory responses and their impact on beta-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus [see comments]
39. Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease
40. Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression
41. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease
42. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease
43. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats
44. Stable gene transfer to the nervous system using a non-primate lentiviral vector
45. Development of a self-inactivating lentivirus vector
46. AAV vectors: is clinical success on the horizon?
47. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
48. Use of adeno-associated virus as a general transduction vector for mammalian cells
49. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
50. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
51. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes
52. Adeno-associated virus vectors: activity and applications in the CNS
53. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters
54. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
55. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
56. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member Neublastin/Artemin
57. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model
58. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
59. Adeno-associated viral vectors
60. Optimization of the helper-dependent adenovirus system for production and potency in vivo
61. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde and immunocytochemical study in the rat
62. Lentiviral vectors: turning a deadly foe into a therapeutic agent
63. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease
64. Immune responses to adenovirus vectors in the nervous system
65. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
66. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
67. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors
68. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
69. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo